A5091321121- Multiple Myeloma Research and Treatments
- Healthcare Systems and Practices
- Tracheal and airway disorders
- Safe Handling of Antineoplastic Drugs
- Protein Degradation and Inhibitors
- Airway Management and Intubation Techniques
- Health, Medicine and Society
- Cultural and political discourse analysis
- Anesthesia and Pain Management
- Gynecological conditions and treatments
- Pharmaceutical Practices and Patient Outcomes
- Nausea and vomiting management
- Intramuscular injections and effects
- Pharmaceutical studies and practices
- PI3K/AKT/mTOR signaling in cancer
- Lung Cancer Treatments and Mutations
- Anesthesia and Sedative Agents
- LGBTQ Health, Identity, and Policy
- Lymphoma Diagnosis and Treatment
- Insect Resistance and Genetics
- Migration, Education, Indigenous Social Dynamics
- Economic and Financial Impacts of Cancer
- Magnetic Properties of Alloys
- Aluminum Alloys Composites Properties
- Cultural and Social Studies in Latin America
Centre Hospitalier Universitaire de Nantes
2023-2025
Yale University
2023-2024
Nantes Université
2022-2023
National Research Council Canada
2023
Centre d'Investigation Clinique de Nantes
2020
With novel therapies including chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies (BsAbs), healthcare providers (HCPs) face complexities managing treatment for patients with relapsed/refractory multiple myeloma (RRMM). This study, among the largest surveys on RRMM, examined unmet needs in care access, barriers to use, decision-making. survey-based study (March-June 2024) enrolled 2284 participants (patients: 1301; HCPs: 983) across 7 countries. Patients >1...
Purpose In France, 40,000 Port-a-Cath (PAC) are inserted each year. These medical devices prone to complications during their insertion or use. The education of patients wearing these could be a lever reduce the risk complications. objective this work was develop, in multi-professional and consensual manner, unique specific skills reference framework for with PAC propose it as tool health professionals. Methods A multidisciplinary working group set up draw skills. first stage consisted...
<h3>Background and importance</h3> Daratumumab, now indicated for first-line treatment of multiple myeloma, has been available in a formulation subcutaneous (SC) injection since April 2021. SC administration must be carried out continuously over 5 min. However, nurses who work the hospital day care report musculoskeletal disorders, preventing continuous infusion thus leading to drug misuse. The increase 55% between 2020 (IV) 2021 preparation volumes daratumumab period from 15 May September...
Background Premedication of cancer therapy against nausea and vomiting (NV) hypersensitivity reaction (HS) is essential for good patient management. However, this prescription not always optimal. Today, as a large part therapies are administered in day hospitals (DH), premedication taken on the treatment injected 30-min infusion. Objective To assess compliance with recommendations intake; to analyse attitude about switching exclusively oral forms at home. Method The study conducted medical...
AbstractThe combination of carmustine, etoposide, cytarabine, and melphalan (BEAM) followed by autologous stem cell transplantation (ASCT) is a commonly used intensification regimen for patients with Hodgkin lymphoma. As etoposide cytarabine dosing are not defined, we conducted retrospective, multicenter study, to compare efficacy toxicity in 130 lymphoma receiving at either 200 mg/m2/d (n = 50), 400 35), or 45). Progression-free survival overall were associated the intensity conditioning....